Form 4 for KROS Keros Therapeutics, Inc.
Accepted 2026-03-11 00:00:00 ET · period of report 2026-03-09 · accession 0001866219-26-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-11 | 2026-03-09 | KROS | Newton Charles W. | Dir | A - Grant | $0.00 | +13.2K | 13.2K | New | $0 |
| D | 2026-03-11 | 2026-03-09 | KROS | Newton Charles W. | Dir | A - Grant | $0.00 | +14.8K | 14.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-09 | A | A | 13,215 | $0.00 | 13,215 | D | — | — | (F1) Represents a restricted stock unit ("RSU") award. The RSUs shall vest over a three-year period in twelve equal quarterly installments with the first such vesting to occur on May 15, 2026, subject to the Reporting Person's continuous service through each such vesting date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2026-03-09 | A | A | 14,788 | $0.00 | 14,788 | D | $11.35 · — to 2036-03-08 | 14,788 Common Stock | (F2) The shares subject to the option shall vest over a three-year period in equal quarterly installments with the first such vesting to occur on June 9, 2026, subject to the Reporting Person's continuous service through each such vesting date. |